A phase III clinical research on renzhujianwei granule in treating chronic atrophic gastritis (qi deficiency, blood stasis and hot depression syndrome)

Renzhujianwei granule in the treating of chronic atrophic gastritis (qi deficiency, blood stasis and hot depression syndrome): randomized, double-blinded and multi-centric clinical research of phase III

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-TRC-12002640

Enrollment

Unknown

Registered

2012-11-01

Start date

2009-05-01

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

chronic atrophic gastritis

Interventions

clinical group(three months):Renzhujianwei granule

control group(three months):simulated agent of Renzhujianwei granule

clinical group(six months):Renzhujianwei granule+ simulated agent of Weifuchu

control group(six months):Weifuchun tablet +simulated agent of Renzhujianwei granule

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. chronic atrophic gastritis with at least one of the following three factors: (1) mild intestinal metaplasia; (2) mild dysplasia; (3) without intestinal metaplasia or dysplasia; 2. the pattern of qi deficiency, blood stasis and heat constraint diagnosed Chinese medicine; 3. the age of 18-65 years; 4. voluntarily signed informed consent.

Exclusion criteria

Exclusion criteria: 1. gastric and duodenal ulcers; 2. moderate and severe metaplasia or hyperplasia of the stomach mucosa; 3. malignant pathological changes; 4. severe primary diseases of heart, liver, kidney and blood systems, abnormal liver and kidney; function (ALT 1.5 times of normal value); 5. psychosis; 6. pregnancy or lactation (contraceptive methods should be taken for female subjects); 7. allergic constitution or allergy to experiment drugs (more than two or any component); 8. other factors determined inappropriate to be included.

Design outcomes

Primary

Measure	Time frame
pathology;Traditional Chinese Medicine syndrome scores;	—

Secondary

Measure	Time frame
mucosal inflammatory change under the gastroscope;HP;	—

Countries

China

Contacts

Public ContactWang changhong

General Hospital of Shenyang Miliary Region

wch239@126.com+86 024 28897620

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026